REHOVOT, Israel, April 17, 2025 /PRNewswire/ -- Sequentify is offering research grants to accelerate high-impact genomic studies through its uniquely fast, easy-to-use, and scalable targeted library preparation technology. Designed to enable the widespread adoption of high-throughput genomic testing, Sequentify's protocol is ideal for large-scale programs conducting targeted sequencing at the population or cohort level.

We invite proposals from research groups conducting genomic DNA studies using human-derived samples, regardless of research field. Eligible areas include, but are not limited to: oncology, rare disease, reproductive health, infectious disease, population screening, and public health.

To qualify, proposed studies must:
- Involve 5,000 human samples or more
- Require Sequentify's off-the-shelf or customized panels (up to 10,000 genomic targets)

Selected applicants will receive:
- Reagents for up to 10,000 samples
- Access to Sequentify's end-to-end analysis software

Submission Guidelines: In up to 250 words, describe how this grant would enhance your research and contribute to your scientific field.

Application period: April 5 – June 20, 2025

Submit applications to: hello@sequentify.com

If you have questions about the grant or your project's eligibility, feel free to reach out to us at the same address—we'd be happy to help.

About Sequentify:

Founded in 2021 as a Weizmann Institute spinoff, Sequentify enables decentralized, population-wide genomic sequencing by providing laboratories with the easiest and quickest solutions available. Their technology facilitates the scaling-up of genomic testing by directly addressing the current pain points in the industry, through sample-prep and software solutions. The company offers panels for oncology and screening applications, and infectious diseases, with a focus on the clinical market. Sequentify is based in Rehovot, Israel. For more information about the company, visit https://www.sequentify.com/.

Media Contact:
Avigayil Simpson
avigayil@sequentify.com

SOURCE Sequentify